New Structure of Business Operations for a Global Pharmaceutical Company

TakedaAs part of its "Transformation into a New Takeda", Takeda Pharmaceutical Company Limited ("Takeda") has implemented several strategies to realize its corporate vision of achieving "sustainable growth" by 2015 through "innovation" and "culture". The latest development came with the recent closing of the Nycomed acquisition, whereby Takeda took another significant step towards globalization. Today, Takeda announces the establishment of the positions of Chief Medical & Scientific Officer (CMSO) and Chief Commercial Officer (CCO), to strengthen the company's governance and business operations as it moves forward to fully integrate the Nycomed organization and become a truly global pharmaceutical company.

In order to further strengthen its global research and development activities, Takeda has abolished the position of Chief Scientific Officer and established the new position of CMSO. Takeda board member Dr. Tadataka Yamada, a medical doctor and scientist with vast global experience in pharmaceutical R&D, has been appointed CMSO to boost research and development productivity by driving innovation and skillfully allocating resources.

In addition, the positions of International Operations (Americas/Europe) and International Operations (North Asia) have been abolished to be replaced by the CCO, who will preside over Takeda's global sales structure (with the exclusion of Millennium and Japanese domestic sales), including most former Nycomed countries and functions. Takeda has appointed board member Dr. Frank Morich as CCO, who has extensive experience at top management in the global pharmaceutical industry. Dr. Morich will drive sales strategies in the important US and EU markets, and also in the fast-growing emerging markets.

Takeda is continually challenging itself to create innovative medicines that transform treatment paradigms to prevent and cure disease, focusing particularly on fields with unmet medical needs, and will continue to globalize its business to deliver its products to patients and health care providers worldwide.

Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

Most Popular Now

Top 20 World Pharma News of 2016

Look back at the most prominent moments from the year 2016. We are proud to announce the 20 most popular World Pharma News from 2016, the most commonly viewed news accord...

Read more

EyeFocus Eye Care Innovation Conference

31 January 2017, London, UK. EyeFocus is holding a one day conference about eye-care innovation to end the second EyeFocus program. The conference is instead of the trad...

Read more

New precision medicine tool helps optimize cancer …

Columbia University Medical Center (CUMC) researchers have created a computational tool that can rapidly predict which genes are implicated in an individual's cancer and ...

Read more

Commonly used drugs lead to more doctor's office, …

Anticholinergic medications, a class of drugs very commonly used by older adults, are linked to an increased rate of emergency department and hospital utilization in the ...

Read more

Roche's emicizumab for haemophilia A meets primary…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 y...

Read more

Sanofi and Boehringer Ingelheim confirm Closing of…

Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) an...

Read more

Diabetes, heart disease, and back pain dominate US…

Just 20 conditions make up more than half of all spending on health care in the United States, according to a new comprehensive financial analysis that examines spending ...

Read more

FDA approves first drug for spinal muscular atroph…

The U.S. Food and Drug Administration has approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare ...

Read more

Novartis invests in next generation therapies to r…

Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...

Read more

Topical treatment activates immune system to clear…

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patie...

Read more

Vaccine shows promising results for early-stage br…

Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer ...

Read more

Anti-aging therapies targeting senescent cells: Fa…

It's an exciting time to be an elderly mouse. Researchers believe that by removing senescent cells (cells with a persistent damage response), which naturally accumulate w...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]